Menu
Search
|

Menu

Close
X

Supernus Pharmaceuticals Inc SUPN.OQ (NASDAQ Stock Exchange Global Market)

39.40 USD
+0.95 (+2.47%)
As of 2:29 AM IST
chart
Previous Close 38.45
Open 38.55
Volume 91,819
3m Avg Volume 177,038
Today’s High 39.70
Today’s Low 38.15
52 Week High 50.03
52 Week Low 24.65
Shares Outstanding (mil) 50.70
Market Capitalization (mil) 2,149.64
Forward P/E 21.31
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.67 Mean rating from 9 analysts

KEY STATS

Revenue (mm, USD)
FY17
133
FY16
215
FY15
147
EPS (USD)
FY17
0.521
FY16
1.760
FY15
0.276
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
21.31
32.90
Price to Sales (TTM)
vs sector
8.51
5.77
Price to Book (MRQ)
vs sector
9.38
5.41
Price to Cash Flow (TTM)
vs sector
20.06
23.42
Total Debt to Equity (MRQ)
vs sector
0.64
16.52
LT Debt to Equity (MRQ)
vs sector
0.64
12.22
Return on Investment (TTM)
vs sector
50.40
14.43
Return on Equity (TTM)
vs sector
61.13
16.13

EXECUTIVE LEADERSHIP

Charles Newhall
Independent Chairman of the Board, Since 2016
Salary: --
Bonus: --
Jack Khattar
President, Chief Executive Officer, Secretary, Director, Since 2005
Salary: $593,042.00
Bonus: --
Gregory Patrick
Chief Financial Officer, Vice President, Since 2011
Salary: $340,583.00
Bonus: --
Stefan Schwabe
Executive Vice-President - Research and Development, Chief Medical Officer, Since 2012
Salary: $366,583.00
Bonus: --
Padmanabh Bhatt
Senior Vice President - Intellectual Property, Chief Scientific Officer, Since 2012
Salary: $347,583.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

1550 E Gude Dr
ROCKVILLE   MD   20850-1339

Phone: +1301.8382500

Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy. In addition, it is developing multiple product candidates in psychiatry to address unmet medical needs and market opportunities for the treatment of impulsive aggression (IA) and for the treatment of attention deficit hyperactivity disorder (ADHD). It is developing SPN-810 (molindone hydrochloride) to treat IA in patients having ADHD. It is developing SPN-812 (viloxazine hydrochloride) as a candidate to treat patients having ADHD. The Company's neurology portfolio consists of Oxtellar XR and Trokendi XR, which are the first once-daily extended release oxcarbazepine and topiramate products, respectively, indicated for epilepsy in the United States market.

SPONSORED STORIES